Report
Oliver Juggins

Diaceutics - 1H22 Results - Sep 2022

We've issued research covering Diaceutics's results for the half-year to 30th June 2022. This period has strongly validated the transition to a platform model, which now represents c.76% of revenue, a level reached about a year ahead of expectations. Not only has revenue grown 25%, but its quality as significantly improved too: 37% of revenue is now derived from multi-year subscription contracts that auto-renew, with an annual break clause. Early indicators lead us to expect low churn and high renewal rates amongst these contracts, so we classify them as recurring revenue. The orderbook is now material for the first time, having grown 6-fold since December 2021 – and already includes £3.8m of revenue for 2H22 and £4.1m for FY23
Underlying
Diaceutics

Provider
Capital Access Group
Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Analysts
Oliver Juggins

Other Reports on these Companies
Other Reports from Capital Access Group

ResearchPool Subscriptions

Get the most out of your insights

Get in touch